Title:
TUMOR VACCINES
Document Type and Number:
WIPO Patent Application WO/2002/055103
Kind Code:
A1
Abstract:
Tumor vaccines containing the following components: (1) fine particles prepared from a solidified tumor material selected from the group consisting of tumor tissues, tumor cells and constituents thereof or a dissolved matter prepared from the tumor material; (2) at least one cytokine and/or cytokine-inducing agent; (c) at least one chemokine and/or chemokine-inducing agent; and (d) myeloid cells and/or blood cells. These vaccines are widely applicable to the prevention of recurrence or treatment of tumors regardless of tumor type, thereby achieving favorable therapeutic effects.
Inventors:
OHNO TADAO (JP)
UCHIMURA EIJI (JP)
UCHIMURA EIJI (JP)
Application Number:
PCT/JP2002/000221
Publication Date:
July 18, 2002
Filing Date:
January 16, 2002
Export Citation:
Assignee:
RIKEN (JP)
OHNO TADAO (JP)
UCHIMURA EIJI (JP)
OHNO TADAO (JP)
UCHIMURA EIJI (JP)
International Classes:
C12N5/07; A61K39/00; A61K39/39; A61P35/00; A61P43/00; C12N5/077; C12N5/0789; C12N5/09; (IPC1-7): A61K39/00; A61K35/12; A61K38/19; A61K35/28; A61K35/14; A61K39/39; A61P35/00; A61P43/00
Domestic Patent References:
| WO2000047226A1 | 2000-08-17 |
Other References:
NOMURA, T. ET AL.: "Chemokines and anti-cancer immunotherapy: anti-tumor effect of EBI1-ligand chemokine (ELC) and secondary lymphoid tissue chemokine (SLC)", ANTICANCER RES., vol. 20, no. 6A, 2000, pages 4073 - 4080, XP002950170
SHIMIZU, K. ET AL.: "Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines", PROC. NATL. ACAD. SCI. USA, vol. 96, no. 5, 1999, pages 2268 - 2273, XP002950171
CAO, X. ET AL.: "Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells", IMMUNOLOGY, vol. 97, no. 4, 1999, pages 616 - 625, XP002950172
NOMURA, T. ET AL.: "Enhancement of anti-tumor immunity by tumor cells transfected with the secondary lymphoid tissue chemokine EBI-1-ligand chemokine and stromal cell-derived factor-1alpha chemokine genes", INT. J. CANCER, vol. 91, no. 5, 1 March 2001 (2001-03-01), pages 597 - 606, XP002950173
SHIMIZU, K. ET AL.: "Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines", PROC. NATL. ACAD. SCI. USA, vol. 96, no. 5, 1999, pages 2268 - 2273, XP002950171
CAO, X. ET AL.: "Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells", IMMUNOLOGY, vol. 97, no. 4, 1999, pages 616 - 625, XP002950172
NOMURA, T. ET AL.: "Enhancement of anti-tumor immunity by tumor cells transfected with the secondary lymphoid tissue chemokine EBI-1-ligand chemokine and stromal cell-derived factor-1alpha chemokine genes", INT. J. CANCER, vol. 91, no. 5, 1 March 2001 (2001-03-01), pages 597 - 606, XP002950173
Attorney, Agent or Firm:
Imamura, Masazumi (Kyobashi-Nisshoku Bldg. 8-, Kyobashi 1-chome Chuo-ku Tokyo, JP)
Download PDF:
Previous Patent: STORAGE STABLE POWDER COMPOSITIONS OF INTERLEUKIN-4 RECEPTOR
Next Patent: ACNE VACCINE
Next Patent: ACNE VACCINE